3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
12
Thoracic
10
Genitourinary
7
Gynecologic
5
Other solid neoplasm
4
Head & Neck
4
Breast
4
Endocrine
2
Dermatologic
2
Tumor-Agnostic
1
Sarcoma
1
Plasma cell
1
NET
1
Lymphoid
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoid Tumor
1
Interventions
lutetium Lu 177 dotatate
28
Magnetic Resonance Spectroscopy
15
Everolimus
10
pembrolizumab
9
Specimen Handling
9
cabozantinib
7
Nivolumab
7
Lutetium-177
6
surufatinib
5
lenvatinib
5
Octreotide
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
lanreotide
4
gallium Ga 68 dotatate
4
amino-acid, glucose, and electrolyte solution
4
X-Rays
4
Lutetium
4
Ipilimumab
4
Injections
4
Fluorodeoxyglucose F18
4
Capecitabine
4
olaparib
3
copper dotatate CU-64
3
atezolizumab
3
Temozolomide
3
Cyclophosphamide
3
Carboplatin
3
pasireotide
2
fludarabine phosphate
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
zimberelimab
×
NET
×
1 year
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled